Current Edition


Bayer backs out of Atara cell therapy deal

Dive Brief: Bayer plans stop developing cancer cell therapies with Atara Biotherapeutics, informing the California biotech company that it will terminate a research collaboration deal …

Continue Reading →

How Bayer lured a biotech away from an IPO and into a buyout

In what has become a common move by large pharmaceutical companies attempting to revitalize their drug research, German healthcare conglomerate Bayer has acquired a small …

Continue Reading →